Tildren

Tildren — Tiludronate Disodium Injectable for Horses

Tildren is a prescription equine intravenous infusion containing tiludronate disodium, a bisphosphonate that reduces abnormal bone resorption. It is approved in the United States to control clinical signs associated with navicular syndrome, a common cause of forelimb lameness in horses.

Tildren is a potent prescription medication, not a routine joint supplement. It should be used only after a veterinarian has completed a full lameness examination, used appropriate diagnostics, and confirmed that the horse’s condition is appropriate for bisphosphonate therapy.

Product Overview

Tildren contains tiludronic acid as tiludronate disodium, a bisphosphonate drug. Bisphosphonates work by inhibiting osteoclast-mediated bone resorption, helping regulate abnormal bone remodeling.

The U.S. product is supplied as a 50 mg lyophilized powder with solvent for reconstitution. After reconstitution with sterile 0.9% sodium chloride, it is administered as a slow, even intravenous infusion through a jugular catheter.

Intended Equine Use

In the United States, Tildren is approved for control of clinical signs associated with navicular syndrome in horses. Navicular syndrome is a common cause of forelimb lameness and involves pain associated with structures in the palmar foot.

Some international labels also describe use for lameness associated with bone and cartilage changes in bone spavin and navicular syndrome. Indications, dosing schedules, and authorization differ by country, so the product label and local regulations must always be followed.

Tildren is not a cure for lameness and does not replace corrective farriery, controlled exercise, pain management, imaging, or treatment of other causes of foot or joint pain.

Administration and Dosing

In the U.S., Tildren is administered as a single intravenous infusion at 1 mg/kg body weight, equivalent to 0.45 mg/lb. It must be infused slowly and evenly over 90 minutes through a jugular catheter to reduce the risk of adverse reactions.

Some European labels use a different regimen: 0.1 mg/kg daily for 10 days, infused slowly over 30 minutes. Do not mix regimens or change the infusion rate without veterinary direction.

Tildren must be administered by a licensed equine veterinarian or under their direct supervision. Incorrect intravenous administration can cause serious complications, including vascular injury, adverse reactions, or collapse.

Safety and Precautions

Do not use Tildren in horses with known hypersensitivity to tiludronate disodium or mannitol. Do not use it in horses intended for human consumption.

Do not use Tildren in horses with impaired kidney function. Renal function should ideally be evaluated before treatment, and the product should not be used in horses under three years of age because effects on the developing skeleton have not been established.

Reported adverse effects include discomfort, mild colic-like signs, muscle tremors, and sweating. These effects are generally dose-related, may appear a few hours after infusion, and are usually short-lived, but the horse should be monitored closely after treatment.

NSAIDs should not be used concurrently with Tildren unless a veterinarian specifically directs it.

Monitoring After Treatment

The horse should be observed closely during and after infusion. Some labels recommend monitoring for several hours afterward because adverse reactions can be delayed.

Contact the treating veterinarian promptly if the horse develops colic signs, severe sweating, tremors, weakness, collapse, difficulty breathing, facial swelling, hives, or worsening lameness.

Tildren should be combined with appropriate hoof care, farriery, controlled exercise, weight management, and follow-up lameness evaluation. It should not be used to enable an unsound horse to continue work.

Competition Compliance

Tildren is a regulated prescription drug and may be prohibited, restricted, or subject to withdrawal requirements in equestrian competition and racing. Rules differ by country, discipline, and sanctioning body.

Before use in a performance horse, obtain written confirmation from the relevant racing commission, equestrian federation, breed registry, or event veterinarian regarding permitted status, detection times, and withdrawal periods. Keep the product label, batch number, veterinary prescription, and treatment records available.

Storage and Handling

Store Tildren according to the manufacturer’s label, protected from light and temperature extremes. Reconstitute only with the specified sterile diluent, use aseptic technique, and discard any unused reconstituted solution according to the label.

Keep out of reach of children, unauthorized personnel, and animals. Dispose of needles, catheters, and unused medication according to local veterinary and environmental regulations.

Why Buy from Equine Pharma World

Equine Pharma World provides clearly described equine veterinary products, secure ordering, and rapid, discreet worldwide delivery. Tildren is supplied for responsible veterinary use only, and buyers must comply with local prescription, import, and competition-medication requirements.

Tildren — a tiludronate disodium intravenous infusion for veterinarian-directed control of clinical signs associated with navicular syndrome in horses.